Holland Capital Invests in Curess
Amsterdam, June 20th, 2024 – Holland Capital participates in Curess, a leading organization in youth care focused on systemic family support. Through the collaboration with Holland Capital, further growth and development can be achieved.
Systemic Family Support
Curess offers specialized ambulatory youth care (such as intensive systemic guidance, ambulatory emergency help, perspective research, and co-parenting investigations) and focuses on strengthening families through practical and directly applicable assistance. Curess operates without waiting lists and can scale its operations up and down quickly, to deliver the desired care swiftly and with high quality. The organization achieves this by applying self-developed software that supports core processes (such as planning) and thus reduces administrative pressure.
Strategic Parntership
With this strategic partnership, Curess has found a partner to achieve its ambitious strategic goals.
Eddy de Bruin, CEO of Curess, states: “With the support of Holland Capital, we can realize our ambitions and help even more young people and families. With their expertise and resources, we are better equipped to significantly increase our impact in youth care. We are committed to providing the necessary support to families to learn to live together better, without waiting lists, through our dedicated professionals.”
Margot Engels, Healthcare Partner at Holland Capital, adds: “We are proud to add Curess to our portfolio. Curess provides crucial support to families in an innovative way, and we look forward to working together on their growth ambitions and further professionalization of their services. Our shared vision is to provide the best possible care and support.”
About Curess
With over 200 registered professionals, Curess offers specialized ambulatory youth care to young people and families to ensure they can live together better. By utilizing personal and innovative methods, Curess strives for a safe and supportive environment for children and their families. Curess is active in the regions of Twente, Midden-IJssel, Oost-Veluwe, Noord-Veluwe, Achterhoek, and Zuid-Drenthe
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and strives for an open, sustainable, and professional relationship with the management teams of the companies they invest in, with the common goal of realizing growth. Holland Capital has offices in Amsterdam and Düsseldorf. With specialized sector teams, it focuses on the Healthcare, Technology, and Agrifood-Tech sectors. They understand the dynamics and opportunities, and have an extensive network in these sectors.
The participation in Curess fits within Holland Capital’s strategy to invest in companies that contribute to societal challenges and create value for society. With this investment, Holland Capital takes an important step in further strengthening its portfolio within the healthcare sector.
Holland Capital investeert in Blyott
Holland Capital investeert in Blyott, dat realtime oplossingen biedt voor het traceren van medische apparatuur binnen zorginstellingen.
Magnus Energy en Ciratum bundelen krachten en nemen het voortouw in de energietransitie
Adviesbureaus Magnus Energy en Ciratum bundelen hun krachten om hun dienstverlening te versterken en te verbreden. Om zo innovatieve, hoogwaardige en holistische oplossingen te bieden aan Nederlandse klanten in de energiesector.
Guiding the energy transition: Magnus Energy and Ciratum unite to lead the way
Magnus Energy and Ciratum have joined forces to elevate their service offerings, delivering innovative, high-quality, and holistic solutions to Dutch customers in the energy sector.
Uman raises EUR 1.9m from Holland Capital to disrupt sales enablement market
Uman, the Belgium-based AI-driven software platform for B2B sales teams, raises 1.9 million euros. The funding round is led by Holland Capital, together with existing investors imec and Seeder Fund.
Gentse AI start-up die de perfecte sales pitch genereert, haalt 1,9 miljoen euro op bij Holland Capital
Uman, het Gentse AI-gedreven softwareplatform voor B2B sales teams, haalt 1,9 miljoen euro op. De financieringsronde wordt geleid door Holland Capital, in combinatie met bestaande investeerders imec en Seeder Fund.
Holland Capital kondigt succesvolle exit van Defibrion aan IK Partners aan
Sinds 2019 heeft het management team van Defibrion op succesvolle wijze samengewerkt met Holland Capital. De aandelen van Defibrion worden verkocht aan IK en Defibrion’s management team.
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl



